Cancer Clinical Trials : Current and Controversial Issues in Design and Analysis book cover
1st Edition

Cancer Clinical Trials
Current and Controversial Issues in Design and Analysis

ISBN 9780367261177
Published March 22, 2019 by Chapman and Hall/CRC
474 Pages 60 B/W Illustrations

SAVE $16.49
was $54.95
USD $38.46

Prices & shipping based on shipping country


Book Description

Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis provides statisticians with an understanding of the critical challenges currently encountered in oncology trials. Well-known statisticians from academic institutions, regulatory and government agencies (such as the U.S. FDA and National Cancer Institute), and the pharmaceutical industry share their extensive experiences in cancer clinical trials and present examples taken from actual trials.

The book covers topics that are often perplexing and sometimes controversial in cancer clinical trials. Most of the issues addressed are also important for clinical trials in other settings. After discussing general topics, the book focuses on aspects of early and late phase clinical trials. It also explores personalized medicine, including biomarker-based clinical trials, adaptive clinical trial designs, and dynamic treatment regimes.

Table of Contents

General Issues
Endpoints for Cancer Clinical Trials
Stephen L. George, Xiaofei Wang, and Herbert Pang

Use of Historical Data
Simon Wandel, Heinz Schmidli, and Beat Neuenschwander

Dong Xi, Ekkehard Glimm, and Frank Bretz

Analysis of Safety Data
Steven Snapinn and Qi Jiang

Early Phase Clinical Trials
Development and Validation of Predictive Signatures
Michael C. Sachs and Lisa M. McShane

Phase I Trials and Dose-Finding
Mark R. Conaway and Nolan A. Wages

Design and Analysis of Phase II Cancer Clinical Trials
Sin-Ho Jung

Late Phase Clinical Trials
Sample Size for Survival Trials in Cancer
Edward Lakatos

Non-Inferiority Trials
Rajeshwari Sridhara and Thomas Gwise

Quality of Life
Diane Fairclough

Personalized Medicine
Biomarker-Based Clinical Trials
Edward L. Korn and Boris Freidlin

Adaptive Clinical Trial Designs in Oncology
J. Jack Lee and Lorenzo Trippa

Dynamic Treatment Regimes
Marie Davidian, Anastasios (Butch) Tsiatis, and Eric Laber


View More



Stephen L. George, Ph.D., is professor emeritus of biostatistics in the Department of Biostatistics and Bioinformatics at the Duke University School of Medicine. For more than 20 years, he was director of biostatistics in the Duke Comprehensive Cancer Center and director of the Statistical Center of the Cancer and Leukemia Group B (CALGB). He has been closely involved in the design, conduct, and analysis of cancer clinical trials and other research projects in cancer throughout his career. He has served on and chaired data monitoring committees for treatment and prevention trials in cancer and other diseases. Dr. George is a fellow of the American Statistical Association and the Society for Clinical Trials. He also served as treasurer and member of the executive committee of the International Biometric Society, president of the Society for Clinical Trials, and biostatistician for the Oncologic Drugs Advisory Committee of the U.S. FDA.

Xiaofei Wang, Ph.D., is an associate professor of biostatistics and bioinformatics at the Duke University School of Medicine, a member of Duke Cancer Institute (DCI), and the director of statistics for the Alliance Statistics and Data Center (Alliance SDC). He has been involved in the design and analysis of cancer clinical trials and translational studies and served on special emphasis panels for NIH and FDA grants. His methodology research focuses on the development of novel designs and methods for biomarker-integrated clinical studies and methods for analyzing patient data from multiple sources. He obtained his Ph.D. in biostatistics from the University of North Carolina at Chapel Hill.

Herbert Pang, Ph.D., is an assistant professor in the School of Public Health, Li Ka Shing Faculty of Medicine (LKSFM) at the University of Hong Kong. Dr. Pang also holds an adjunct faculty position in the Department of Biostatistics and Bioinformatics at Duke University. He has been involved in the design, monitoring, and analysis of cancer clinical trials, translational, and big data-omics research in cancer for CALGB, Alliance SDC, DCI, and LKSFM. He has served on the editorial board of the Journal of Clinical Oncology and has received several honors, including the U.S. Chinese Anti-Cancer Association-Asian Fund for Cancer Research Scholar Award. He obtained his Ph.D. in biostatistics from Yale University and B.A. in mathematics and computer science from the University of Oxford.


"The chapters on endpoints and safety are a must read for anyone working in this field. And for statisticians involved in the design of cancer trials, the diverse options of design and sample size calculations are well covered."
~International Society for Clinical Biostatistics

"This book provides a comprehensive summary of common controversial issues frequently encountered in oncology trials. Individual issues are addressed by well-known statisticians from academic institutions, regulatory, and government agencies and pharmaceutical industry. In summary, this is an excellent book covering commonly encountered controversial issues for cancer clinical trials. It can be an excellent resource for statisticians working in oncology drug development."
~Journal of Biopharmaceutical Graphics, Steven Sun